
Pediatric Dermatology Efficacy
Taltz is the first IL-17A antagonist approved for the treatment of pediatric patients as young as age 6 with moderate to severe plaque psoriasis (PsO)1
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
FOR PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Half of Taltz pediatric patients achieved PASI 100 at week 121
PASI 100 results consistent with adult registration trials
*P<.001 vs placebo at week 12.
Co-primary endpoints=PASI 75 at week 12 and sPGA 0,1 at week 12.
Week 12 results from patients treated with weight-based dose of 160 mg, 80 mg, or 40 mg of Taltz at week 0, followed by 80 mg, 40 mg, or 20 mg every 4 weeks through week 60.1
ADDITIONAL RESULTS AT WEEK 12
81% of patients taking Taltz achieved sPGA 0,1 vs 11% who received placebo.3
Adult PsO Registration trial data
SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Data on file. Lilly USA, LLC. DOF-IX-US-0207. 3. Data on file. Lilly, USA, LLC. DOF-IX-US-0213.